CEL-SCI Corp Insider Buying: CEO Geert Kersten Acquires Additional Shares

Geert Kersten, CEO of CEL-SCI Corp, purchased 29,197 shares of the company on July 25, 2025, bringing his total ownership to 72,835 shares. This insider buying trend is positive, with 1 insider buy and 0 insider sells over the past year. CEL-SCI Corp's primary product, Multikine, is an investigational immunotherapy for head and neck cancer. The company has a market cap of $46.213 million, with shares trading at $6.85 each.

In a significant move, Geert Kersten, the CEO of CEL-SCI Corporation (CVM), purchased 29,197 shares of the company on July 25, 2025. This purchase, valued at $199,999, brings his total ownership to 72,835 shares. This insider buying trend is positive, with only one insider buy and no insider sells over the past year [1].

The acquisition of these shares comes amidst CEL-SCI's ongoing research into Multikine, an investigational immunotherapy for head and neck cancer. The company's market capitalization stands at $46.213 million, with shares trading at $6.85 each [1].

The recent insider buying activity has sparked interest among investors, who are closely monitoring the company's progress in the biotech sector. The latest offering announcement by CEL-SCI, totaling $5.7 million, has also drawn attention. This capital raise is expected to fund critical clinical trials, reflecting the company's commitment to advancing its immunotherapy candidate [1].

Geert Kersten's purchase is notable as it is his first insider buy in the past twelve months. His confidence in the company's prospects is a positive signal to investors, as insider buying often indicates a belief in the company's future performance. The fact that no insider sales have been reported in the past year further underscores this positive sentiment [2].

CEL-SCI's recent financial moves, including the insider buying and the capital raise, indicate a strategic approach to funding research and development. As the company continues to make progress in its immunotherapy program, investors will be watching closely for further updates on how the funds will be utilized and how these developments might impact the stock price.

References:
[1] https://www.quiverquant.com/news/CEL-SCI+Corporation+Stock+%28CVM%29+Opinions+on+%245.7+Million+Offering+Announcement
[2] https://www.nasdaq.com/articles/monday-7-28-insider-buying-report-cvm-loop